Campos, Paula de Melo; Machado Neto, João Agostinho 
; Scopim-Ribeiro, Renata; Visconte, Valeria; Tabarroki, Ali; Duarte, Adriana S. S; Barra, Flávia F. C; Vassalo, José; Rogers, Heesun J; Lorand-Metze, Irene; Tiu, Ramon V; Costa, Fernando F; Saad, Sara T. Olalla; Traina, Fabiola
Fonte: Leukemia Research. Unidade: FMRP
Assuntos: APOPTOSE (EFEITOS DE DROGAS), PROTEÍNAS PROTO-ONCOGÊNICAS, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMPOS, Paula de Melo et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, v. 38, n. 10, p. 1245-1251, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.leukres.2014.07.010. Acesso em: 23 out. 2025.APA
Campos, P. de M., Machado Neto, J. A., Scopim-Ribeiro, R., Visconte, V., Tabarroki, A., Duarte, A. S. S., et al. (2014). Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leukemia Research, 38( 10), 1245-1251. doi:10.1016/j.leukres.2014.07.010NLM
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2025 out. 23 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010Vancouver
Campos P de M, Machado Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte ASS, Barra FFC, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Saad STO, Traina F. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412 [Internet]. Leukemia Research. 2014 ; 38( 10): 1245-1251.[citado 2025 out. 23 ] Available from: https://doi.org/10.1016/j.leukres.2014.07.010
